Cytosorbents (CTSO) to Release Quarterly Earnings on Thursday

Cytosorbents (NASDAQ:CTSO) is projected to post its quarterly earnings results after the market closes on Thursday, March 6th. Analysts expect Cytosorbents to post earnings of ($0.07) per share and revenue of $10.09 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Cytosorbents Stock Performance

NASDAQ:CTSO opened at $1.10 on Thursday. The stock has a 50 day simple moving average of $1.03 and a 200 day simple moving average of $1.04. The stock has a market cap of $60.15 million, a P/E ratio of -3.06 and a beta of 0.61. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $1.61. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.

Analysts Set New Price Targets

A number of research analysts recently commented on CTSO shares. StockNews.com assumed coverage on shares of Cytosorbents in a research note on Saturday, February 22nd. They issued a “hold” rating for the company. D. Boral Capital reissued a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a report on Tuesday. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Cytosorbents has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.